Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    New Treatment For Painful Diabetic Neuropathy: Nevro (NVRO) Overview

    New Treatment For Painful Diabetic Neuropathy: Nevro (NVRO) Overview

    FromSchwab Network

    Start listeningView podcast show

    New Treatment For Painful Diabetic Neuropathy: Nevro (NVRO) Overview

    FromSchwab Network

    ratings:
    Length:
    7 minutes
    Released:
    Jul 22, 2021
    Format:
    Podcast episode

    Description

    The FDA recently approved Nevro (NVRO) treatment for chronic pain from Painful Diabetic Neuropathy (PDN). The treatment is called HFX™ and is now the only spinal cord stimulation system treatment for PDN that is approved by the FDA. Keith Grossman, Chairman and CEO of Nevro, discusses HFX™, as well as what this treatment means for diabetic patients. Nevro stock also hit an all-time high in December 2020. Tune in to find out more.
    Released:
    Jul 22, 2021
    Format:
    Podcast episode

    Titles in the series (100)

    A unique lineup of financial news and education programs, all available to stream without a subscription. Listen to industry experts track market action and interpret how it may apply to your investment portfolio. Get real-time insights, commentary, and exclusive access to CEOs, analysts, and market experts. Empowering Every Investor and Trader. Every Market Day. Produced by TD Ameritrade Media Productions Company, a wholly-owned subsidiary of TD Ameritrade Holding Corporation. TD Ameritrade Holding Corporation is a wholly owned subsidiary of The Charles Schwab Corporation. TD Ameritrade Media Productions Company is not a financial adviser, registered investment advisor, or broker-dealer. THE TD AMERITRADE NETWORK SITE, CONTENT, APPS, AND RELATED SERVICES, ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS, WITHOUT WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. This is not an offer or solicitation in any jurisdiction where we are not authorized to do business or where such offer or solicitation would be contrary to the local laws and regulations of that jurisdiction, including, but not limited to persons residing in Australia, Canada, Japan, Saudi Arabia, UK, and the countries of the European Union. All TD Ameritrade Network content © TD Ameritrade Network. All rights reserved.